Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TKM-080301 · 2 trials · 9 indications
Laboratory assessments
| Arm | Type | Description |
|---|---|---|
| Phase 1 Escalation / Phase 2 Expansion | EXPERIMENTAL | Phase 1 - dose escalation with intravenous infusion of TKM-080301 to determine MTD. Phase 2 - dose expansion at the MTD. |
| TKM-080301 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TKM-080301 | DRUG | TKM-080301 intravenous infusion |
Key Inclusion Criteria: * Child-Pugh class of A * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5.0 × ULN * Total bilirubin ≤3.0 mg/dL * Platelets ≥75,000 /mL * International Normalized Ratio (INR) ≤1.7 ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
TKM-080301 is an investigational small molecule being studied for the treatment of cancer, including hepatocellular carcinoma. It has been evaluated in Phase 1 clinical trials for advanced hepatocellular carcinoma and for neuroendocrine tumors and adrenocortical carcinoma. It is not approved and remains in clinical development.
TKM-080301 is being developed by Arbutus Biopharma Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ABUS. The company has conducted Phase 1 clinical trials of this investigational drug for cancer indications.
TKM-080301 is in Phase 1 clinical development. It has completed two Phase 1 trials, one in neuroendocrine tumors and adrenocortical carcinoma and another in advanced hepatocellular carcinoma. The drug is investigational and has not been approved by regulatory authorities.
TKM-080301 has been studied in two completed Phase 1 trials. NCT01262235 evaluated the drug in patients with neuroendocrine tumors and adrenocortical carcinoma, enrolling 68 participants in the United States. NCT02191878 studied the drug in advanced hepatocellular carcinoma, enrolling 43 participants across the United States, Canada, China, Singapore, South Korea, and Taiwan.
TKM-080301 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is a small molecule being developed by Arbutus Biopharma Corporation for oncology indications.